Excerpt

By following one child’s case, researchers learned that her KCNQ2 variant caused overactive Kv7.2 channels and found that a medication could calm this overactivity in lab-grown cells.

What It’s About

This case report closely followed the medical history of a 3-year-old girl who was suffering from seizures and developmental delay. Genetic testing revealed she had a KCNQ2 variant initially classified in 2021 as a variant of uncertain significance (VUS). Because her symptoms strongly suggested the variant may be disease-causing, researchers wanted to confirm its pathogenicity and understand how it was affecting channel function.

To do this, they generated cells expressing her specific KCNQ2 variant and recorded their electrical activity. Their experiments showed that the Kv7.2 channel was overactive in these cells, suggesting that the variant (I134N) was causing a gain-of-function (GoF) effect. When they applied the Kv7.2 channel blocker amitriptyline, overactivity decreased in the channel.

Why It Matters

KCNQ2-related disorders are caused by different types of KCNQ2 variants. While many individuals have variants that reduce channel function (loss-of-function variants), some variants actually increase channel activity (gain-of-function variants). This distinction is important because gain and loss-of-function variants will likely require different treatment strategies.

The Quick Term

Case Report: A scientific article that focuses on one patient to better understand a disease or treatment.

Link
Read Article